Figure 3
From: Effect of non-repetitive linker on in vitro and in vivo properties of an anti-VEGF scFv
Binding kinetics of Bevacizumab, L1 and L2 fragments to their antigen, VEGF. (A) Obtained kinetic parameters. Sensogram overlays for (B) bevacizumab (C) L1 and (D) L2. Antibody concentrations are expressed on corresponding curves. Analyses were repeated 2 times.
